PBM Spread Pricing Skims Hidden Margins on Every Prescription

Pharmacy Benefit Managers pocket the difference between what they charge health plans for a prescription and what they actually pay the dispensing pharmacy. A PBM might bill a state Medicaid plan $100 for a generic drug while reimbursing the pharmacy only $20, keeping the $80 "spread" as undisclosed profit. This is not a transparent service fee; it is an opaque margin hidden inside the drug transaction itself, and the plan sponsor has no visibility into the actual acquisition cost. This matters because the spread inflates drug spending for employers, unions, and government programs that believe they are getting competitive pricing. State audits have repeatedly uncovered hundreds of millions in spread pricing overcharges. Ohio's 2018 audit found its Medicaid managed care PBMs retained $224 million in spread on generic drugs in a single year. That money came directly from taxpayer-funded Medicaid budgets that could have covered additional patients or services. The downstream pain is concrete: when a self-insured employer's drug spend is inflated by hidden spreads, they raise employee premiums, increase copays, or cut benefits elsewhere. Employees pay more out of pocket for the same prescriptions, and some skip medications entirely because of cost. A 2023 Kaiser Family Foundation survey found 29% of adults reported not taking medications as prescribed due to cost. Spread pricing persists because PBM contracts are protected by confidentiality clauses that prevent plan sponsors from auditing the actual reimbursement amounts paid to pharmacies. The three largest PBMs — CVS Caremark, Express Scripts, and OptumRx — control roughly 80% of the market and have no competitive incentive to disclose spreads voluntarily. Even when states pass spread-pricing transparency laws, PBMs shift margin to other opaque mechanisms like DIR fees or administrative charges. The structural root cause is that PBMs serve two masters — they are hired by plan sponsors to reduce drug costs, but they profit by maximizing the gap between what they charge and what they pay. This fundamental conflict of interest is baked into the business model, and without mandatory pass-through pricing requirements, there is no mechanism to align PBM incentives with the payers they claim to serve.